Evidence map›Paper›PMID 39373599›Full record

ReviewImmunotherapy2024

A lesson from fatal invasive fungal infections after CAR-T cell therapy: a case report and literature review.

Zhengfeng Hou, Danchen Meng, Min Ruan, Xinglin Liang, Jing Ni, Dai Jifei, Zhonghui Wu, Ruixiang Xia, Jian Ge, Zhangbiao Long

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhengfeng HouDepartment of hematology, the first affiliated hospital of Anhui medical university, Hefei, 230022, China.
Danchen MengDepartment of hematology, the first affiliated hospital of Anhui medical university, Hefei, 230022, China.
Min RuanDepartment of hematology, the first affiliated hospital of Anhui medical university, Hefei, 230022, China.
Xinglin LiangDepartment of hematology, the first affiliated hospital of Anhui medical university, Hefei, 230022, China.
Jing NiDepartment of hematology, the first affiliated hospital of Anhui medical university, Hefei, 230022, China.
Dai JifeiDepartment of hematology, the first affiliated hospital of Anhui medical university, Hefei, 230022, China.
Zhonghui WuDepartment of hematology, the first affiliated hospital of Anhui medical university, Hefei, 230022, China.
Ruixiang XiaDepartment of hematology, the first affiliated hospital of Anhui medical university, Hefei, 230022, China.
Jian GeDepartment of hematology, the first affiliated hospital of Anhui medical university, Hefei, 230022, China.
Zhangbiao LongDepartment of hematology, the first affiliated hospital of Anhui medical university, Hefei, 230022, China.

Funding

Clinical Science Fund of Anhui Medical University 2023xkj138National Natural Science Foundation of China 81900118Research Fund of Anhui Institute of translational medicine 2023zhyx-C39Scientific Research Project of Anhui Provincial Health Commission AHWJ2023A30067
6 · The paper itself

Abstract

CD19 chimeric antigen receptor T (CAR-T) cell therapy represents an effective approach to treating patients with relapsed or refractory B-cell hematologic malignancies. Nevertheless, owing to the immunosuppressive effects of this regimen, patients undergoing CD19 CAR-T cell therapy may face an elevated risk of invasive fungal infections, which involve fungi penetrating the host's tissues or bloodstream, leading to life-threating infectious diseases. Herein, we present the case of a 17-year-old male diagnosed with acute lymphoblastic leukemia, who subsequently experienced a fatal invasive fungal infection following administration of CAR-T cell therapy. Furthermore, we delve into the identification of risk factors, implementation of preventive measures and exploration of therapeutic interventions for invasive fungal infections after CAR-T cell therapy.

Indexed as

Immunotherapy, AdoptiveInvasive Fungal InfectionsAdolescentAntigens, CD19Fatal OutcomeHumansMalePrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenAntigens, CD19Receptors, Chimeric Antigenaspergillus flavusCAR-T cell therapycase reportimmunotherapyinvasive fungal infections

Identifiers

PMID39373599
PMCPMC11492695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.